NKT Therapeutics
Latest round
- Series A
Last raised
- Mar 2009
Total raised
- $8M
Investors
- 2
About NKT Therapeutics
Founded in 2008 and headquartered in Waltham, Massachusetts, NKT Therapeutics, Inc specializes in immunotherapy solutions targeting natural killer T cells. The company has completed a total of 4 deals since its inception, with the most recent deal occurring on February 13, 2013.NKT Therapeutics, Inc focuses on developing immunotherapies that leverage natural killer T cells to provide effective treatment options for cancers and autoimmune diseases.The company generates revenue primarily through partnerships and collaborations in the biotechnology sector. The company is actively designing and preparing to launch additional therapies aimed at expanding its treatment options by 2024. Additionally, NKT Therapeutics is looking to penetrate new markets, particularly in Europe and Asia, to broaden the accessibility of its innovative therapies.
Who invested in NKT Therapeutics
2 investors across 1 round
See all investors in NKT Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Mar 30, 2009
Amount
$8M
Investors
Questions about NKT Therapeutics
Who invested in NKT Therapeutics?
NKT Therapeutics has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has NKT Therapeutics raised?
NKT Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did NKT Therapeutics last raise money?
NKT Therapeutics's most recent round on record is a Series A, in Mar 2009.
What does NKT Therapeutics do?
Founded in 2008 and headquartered in Waltham, Massachusetts, NKT Therapeutics, Inc specializes in immunotherapy solutions targeting natural killer T cells.
Where is NKT Therapeutics headquartered?
NKT Therapeutics is headquartered in Waltham, US.
Which VCs invest in companies like NKT Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at NKT Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like NKT Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.